CA

Chetanbhai Arvindbhai Soni

Director Director DIN 10079592
DIN 10079592 First appointment Mar 2023 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Past companies 2 historical roles
Total affiliations 2 Since Mar 2023
Shareholding value •••• Premium profile

About Chetanbhai Arvindbhai Soni

Data last updated:

Chetanbhai Arvindbhai Soni was a Director at Zseps Pharmaceuticals Private Limited (2023–2024) and Director at 24Ct Naturals Private Limited (2023–2024). The companies operate in Pharma and Wood.

DIN 10079592
Primary Designation Director
Industry Pharma
First Appointment 19 Mar 2023

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director19 Mar 20232023₹32.7 Lakh (FY 2025)Active
24Ct Naturals Private Limited U20237GJ2023PTC140745
Director01 May 20232023Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Zseps Pharmaceuticals Private Limited
24Ct Naturals Private Limited
Premium access

Shareholding and investment profile for Chetanbhai Arvindbhai Soni

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Chetanbhai Arvindbhai Soni

Chetanbhai Arvindbhai Soni was first appointed on 19 Mar 2023 as Director at Zseps Pharmaceuticals Private Limited.

Chetanbhai Arvindbhai Soni held 2 earlier board appointments: Zseps Pharmaceuticals Private Limited (Director, 19 Mar 2023 to 25 Dec 2024); 24Ct Naturals Private Limited (Director, 01 May 2023 to 11 Oct 2024).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available